$ACT Headlines 10 biggest S&P 500 winners and losers

New Post Public Reply Private Reply Replies (0) Message Board

Jul 10, 2014 at 9:51 AM

$ACT Headlines

10 biggest S&P 500 winners and losers for 2014 10:44 a.m. July 1, 2014 - Philip van Doorn
Affiliated Managers Group to join S&P 500 5:33 p.m. June 24, 2014 - Wallace Witkowski
10 best-performing S&P 500 stocks of 2014 2:38 p.m. June 2, 2014 - Philip van Doorn
Pfizer's plan to relocate after merger deal draws lawmakers' fire 11:30 a.m. May 9, 2014 - Russ Britt
Corner drug store may move overseas to save on taxes 6:31 a.m. April 16, 2014 - Al Lewis
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
Actavis acquires Silom Medical for $100 million 10:19 a.m. April 1, 2014 - MarketWatch.com
The 10 most overbought stocks in the S&P 500 index 12:19 p.m. March 25, 2014 - The Trading Deck
UK drug rejection, patent concerns take a bite out of Celgene shares 1:33 p.m. March 14, 2014 - Russ Britt
Mylan to start selling generic Celebrex in May 7:23 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - Russ Britt
Staples awash in red; eBay up as Icahn posts new letter 5:09 p.m. March 6, 2014 - Sue Chang
Icahn Enterprises reports profit up 144% in 2013 11:23 a.m. March 3, 2014 - MarketWatch
Citadel hedge fund’s recent moves 12:12 p.m. Feb. 25, 2014 - Insider Monkey
Stocks rally; S&P 500 ends right below record 5:46 p.m. Feb. 24, 2014 - Victor Reklaitis
U.S. stock market is starting to ride a tech M&A wave 6:31 a.m. Feb. 24, 2014 - Wallace Witkowski
Actavis continues hot streak with better-than-expected earnings 12:21 p.m. Feb. 20, 2014 - Russ Britt
Actavis swings to loss on charges, write-downs 9:04 a.m. Feb. 20, 2014 - MarketWatch.com
Pharma megamergers bring higher profits, better returns, study says 2:59 p.m. Feb. 19, 2014 - Russ Britt
Actavis, Forest shares continue their climb in aftermath of $25 billion deal 12:03 p.m. Feb. 19, 2014 - Russ Britt

Synergy Pharmaceuticals' Plecanatide to Move into Phase III - Analyst Blog 5:10 p.m. July 9, 2014 - Zacks.com
InsiderInsights.com Daily Round Up: 7/7/14 1:21 p.m. July 8, 2014 - Seeking Alpha
M&A Activity Hits 7-Year Peak: Next 3 Takeover Targets - Analyst Blog 12:29 p.m. July 7, 2014 - Zacks.com
Will 2014’s Top Performers Keep Performing? 2:01 a.m. July 6, 2014 - InvestorPlace.com
Impax Acquires Generic Products from Actavis - Analyst Blog 12:00 p.m. July 3, 2014 - Zacks.com
Teva files a citizen petition regarding approvability of generic versions of Copaxone 8:28 a.m. July 3, 2014 - Seeking Alpha
What Stocks Top Funds Are Buying Now 6:09 p.m. July 2, 2014 - Investors Business Daily
Taro Pharmaceuticals: Last Week's Move Is Only The Beginning 9:05 a.m. July 2, 2014 - Seeking Alpha
Allergan Can Go It Alone 6:09 a.m. July 2, 2014 - Barrons.com
Why Actavis (ACT) Stock May Move Higher Today 8:42 a.m. July 1, 2014 - TheStreet.com
Actavis, Forest To Sell or Relinquish Generics Rights 5:34 p.m. June 30, 2014 - The Wall Street Journal Interactive Edition
Actavis Says Holders of 73% of Forest Shares Elect Stock 9:29 a.m. June 30, 2014 - The Wall Street Journal Interactive Edition
Many IBD 50 Stocks Struggle To Climb After Breakouts 6:08 p.m. June 27, 2014 - Investors Business Daily
Auxilium and QLT to Merge on Tax Saving Attractions - Analyst Blog 12:10 p.m. June 27, 2014 - Zacks.com
Orexo sues Actavis over Zubsolv patent 10:48 a.m. June 27, 2014 - Seeking Alpha
Top Analyst Upgrades and Downgrades: Alcoa, Cigna, Intel, Molina, Teva, UnitedHealth and More 7:27 a.m. June 27, 2014 - 247WallSt.com
Why These 5 Mutual Funds Are Beating the S&P 500 5:34 a.m. June 27, 2014 - InvestorPlace.com
Novo, Other Medicals Display Healthy Action 5:41 p.m. June 26, 2014 - Investors Business Daily
Diamond Hill Capital Comments on Actavis Inc 10:49 a.m. June 26, 2014 - GuruFocus.com
Ampyra faces generic threat 7:11 a.m. June 26, 2014 - Seeking Alpha

Actavis Confirms Generic Ampyra® Patent Challenge 4:05 p.m. July 8, 2014 - PR Newswire - PRF
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma 5:30 a.m. July 4, 2014 - PR Newswire - PRF
Impax Acquires Two Products from Actavis 4:05 p.m. July 2, 2014 - PR Newswire - PRF
Actavis Completes Acquisition of Furiex Pharmaceuticals 8:46 a.m. July 2, 2014 - PR Newswire - PRF
Actavis Announces Final Stockholder Merger Consideration Election Results in Connection with Forest Laboratories Acquisition 8:00 a.m. July 2, 2014 - PR Newswire - PRF
Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger 3:15 p.m. July 1, 2014 - BusinessWire - BZX
Fitch Rates Forest Labs Bonds 'BBB-', Affirms Actavis at 'BBB-'; Outlook Stable 10:08 a.m. July 1, 2014 - BusinessWire - BZX
Actavis plc Appoints New Members and Announces Changes to Board of Directors Following Close of Forest Laboratories, Inc. Acquisition 9:00 a.m. July 1, 2014 - PR Newswire - PRF
Actavis Completes Forest Laboratories Acquisition 8:20 a.m. July 1, 2014 - PR Newswire - PRF
Stocks Coverage on the Pharma Industry -- Research on Zoetis, Mylan, AVANIR Pharma, and Actavis 6:50 a.m. July 1, 2014 - PR Newswire - PRF
Actavis and Forest Receive U.S. FTC Clearance for Actavis’ Proposed Acquisition of Forest 5:15 p.m. June 30, 2014 - BusinessWire - BZX
Actavis and Forest Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Forest 5:15 p.m. June 30, 2014 - PR Newswire - PRF
Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results 8:30 a.m. June 30, 2014 - BusinessWire - BZX
Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results 8:30 a.m. June 30, 2014 - PR Newswire - PRF
Actavis to Host Second Quarter 2014 Earnings Conference Call and Webcast 8:00 a.m. June 30, 2014 - PR Newswire - PRF
Actavis Confirms Generic Zubsolv® Patent Challenge 7:30 a.m. June 30, 2014 - PR Newswire - PRF
Leadership Appointments, Approved Acquisitions, Licensing Agreements, Technical UPdate, and Response to Tender Offer Announcement - Analyst Notes on Actavis, Forest, Vertex, MannKind and Gentiva 5:20 a.m. June 26, 2014 - PR Newswire - PRF
Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600 6:50 p.m. June 24, 2014 - PR Newswire - PRF
Actavis and Forest Announce Tentative Election Deadline of June 27, 2014 8:30 a.m. June 24, 2014 - BusinessWire - BZX
Actavis and Forest Announce Tentative Election Deadline Of June 27, 2014 8:30 a.m. June 24, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Labcorp Lifts 2026 Guidance Amid Strong Q3 Performance

Labcorp's Q3 Numbers Speak Loud and Clear Another quarter, another robust set of numbers for Labcorp (NYSE:LH). The company is strutting into the spotlight with third-quarter 2026 results that have investors nodding in approval. Revenue surged to $3.81 billion, marking a 6.9% increase from the prior year's $3.56 billion. And get this: adjusted EPS jumped 14.5%, clocking...

SoftwareOne Triumphs in 2026 GitHub Partner Awards

SoftwareOne Nabs Prestigious GitHub Honor Outta nowhere, SoftwareOne's been lashed onto the center stage, bagging GitHub's Global Channel Sales Partner of the Year for 2026. This ain't just another shiny trophy on the shelf; it's a solid nod to their grit and strategy. Now, if good old GitHub says you're their top dog, you're obviously doing something right. Not bad for a...

AppLovin Faces Class Action: AI Growth Claims Under Fire

AppLovin's AI Jackpot: A Busted Flush? This year's been a rollercoaster at AppLovin Corporation, and not the fun kind. Let me tell ya, investors bought into a dream—a self-sustaining, profit-churning machine based on AI advertising models. Unfortunately, reality came around like a bad penny, and suddenly, their 'virtuous cycle' feels more like a busted flush....

HERVolution's HERV-K Antigens: A Cancer Breakthrough?

Digging into HERVolution's Game-Changing Data Picture HERVolution in the spotlight, rolling out data that could shake up our approach to cancer immunotherapy. The big headline? HERV-K antigens might just be the whistle-blower we've been looking for to get the immune system off the bench and onto the field. How's that for a kick in the conventional wisdom of cancer...

QFIN Faces Lawsuit Over Broken Promises and Revenue Plunge

Unmasking the Hype: QFIN's Pledge and Performance Investors, gather 'round because QFIN's latest uproar ain't pretty. The folks over at Qfin Holdings have found themselves in hot water, facing a class action lawsuit for allegedly pulling the wool over investors' eyes. Between March and August 2026, they promised a rock-solid ship braving China’s regulatory storm. Turns...

Lynk Pharmaceuticals' Zemprocitinib Shines in Phase III RA Trial

A Deep Dive into Lynk Pharmaceuticals' Latest Revelation Lynk Pharmaceuticals just dropped a bombshell with their latest Phase III trial results for zemprocitinib. This selective JAK1 inhibitor seems to be bringing some serious game in the fight against moderate-to-severe rheumatoid arthritis (RA), especially for folks who haven't had much luck with biologics. The drug...

Faith on Trial: La Luz del Mundo Faces Court Ruling

A Legal Battle Over Religious Freedom When folks start talking about religion intertwining with law, things get real tricky, real quick. The La Luz del Mundo church is knee-deep in such a legal tussle. On October 28, 2026, the United States District Court for the Southern District of New York gave a nod to the prosecution, denying the church's pretrial motions. What we've...

Corgi Insurance Eyes $100B Auto Market with New Launch

Leaping Into a Booming Market Well, it looks like someone lit a fire under Corgi Insurance, and they're ready to chase bigger bones. They’ve just rolled out a product called Corgi Business Auto, signaling quite a bold move into the hefty, nearly $100 billion U.S. commercial auto insurance arena. Now, as an old hand at this game, my ears perk up whenever I see a player...

Pave and Levels.fyi Unite: Revolutionize Pay Decisions

Diving straight into the heart of it, here's a move in the business world that's all but marking its territory on the compensation landscape. Pave, already a big player in agentic compensation management, is shaking hands with Levels.fyi, a platform prized for its real-deal compensation data detailed down to the company, level, location, and skill. These folks are...

Honeywell Aerospace Posts Solid Q3, Raises Guidance

Honeywell Aerospace Surprises with Strong Third Quarter In a world where numbers are often as slippery as a greased pig, Honeywell Aerospace (NASDAQ:HONA) has managed to pin down a surprisingly robust third quarter. Let’s break it down: they’ve claimed sales of a cool $4.6 billion, reflecting a 2% bump both in reported and organic revenue from the previous year, and...